Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 5,299
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
Mike Kyewalyanga
ID: UNCST-2021-R013531
 Factors associated with virological non-suppression among HIV- Positive children under 5 years on antiretroviral therapy in Mbarara Regional Referral Hospital
REFNo: HS1584ES

1.To determine the proportion of virological non-suppression among HIV positive children under 5 years who have been on ART for at least 6 months, in the ISS clinic of Mbarara Regional Referral Hospital.

2.To determine the factors associated with virological non-suppression among HIV positive children under 5 years who are receiving ART from ISS clinic of Mbarara Regional Referral Hospital.
3.To determine the perceptions of health-care providers and parents/guardians on factors associated with virological non-suppression among HIV positive children under 5 years who are receiving ART from ISS clinic of Mbarara Regional Referral Hospital.

 Uganda 2021-08-25 2024-08-25 Medical and Health Sciences Non-Clinical Trial Degree Award
Luz Azlor del Valle
ID:
GAFSP Private Sector Window Uganda Impact Evaluation - Baseline
REFNo: SS943ES

The primary research question is – what is the impacts of an expansion in the fertiliser business on smallholder farmers. The purpose of the evaluation is to account for the interventions and support provided and to derive lessons and recommendations to improve future impact. To meet these objectives the eventual impact evaluation will attempt to answer the following evaluation questions:
1. How does the project affect yields?
2. How does the project affect household income and poverty status of farmers?
3. What is the project’s impact on food security and nutrition?
4. What is the project’s impact on women’s status and empowerment?
 Spain 2021-08-25 2024-08-25 Social Science and Humanities Non-Clinical Trial Non-degree Award
Jayne Ellis
ID: UNCST-2021-R013987
 “Integrated management of cryptococcal and opportunistic infections to improve outcomes in advanced HIV disease (IMPROVE study)”
REFNo: HS1607ES

1) To generate evidence on the safety (adverse events) and feasibility (adherence and tolerability) of 1HP (one month of isoniazid and rifapentine) for TB preventative therapy (TPT) amongst adults with HIV-associated cryptococcal meningitis.
2) To generate preliminary data on potential secondary benefits (reduced loss to follow-up, reduced active TB disease, reduced mortality due to TB) of early (inpatient initiation) 1HP TPT as compared to standard (outpatient initiation) 1HP TPT amongst adults with HIV-associated cryptococcal meningitis.

UK 2021-08-25 2024-08-25 Medical and Health Sciences Clinical Trial Degree Award
Moses Joloba Lutaakome
ID: UNCST-2022-R011558
 Bacterial and Host Determinants in TB Transmission: Immune Phenotypes Associated with Exposure to High and Low Transmission Strains of MTB - Uganda
REFNo: HS1498ES

The goal of this study is to identify the bacterial and host factors that promote transmission of tuberculosis (TB), a necessary first step towards developing drugs and vaccines that prevent the inter-person spread of Mycobacterium tuberculosis (Mtb). This study has five specific aims:

Aim 1: Determine the extent to which household transmission is responsible for co-prevalent and incident TB cases caused by Mtb strains that are genetically distinct from those isolated from the index cases within the same household.

Aim 2: Investigate the in vitro immune phenotype of transmitted versus not-transmitted Mtb strains in households stratifying for HIV status.

Aim 3: Characterize the innate macrophage response to high and low transmission strains and the T-cell response in persons with known household exposure to high and low transmission isolates and the impact of HIV infection.
Aim 4: Identify the component of Mtb genes that aid in bacterial survival in aerosols.
Aim 5: Investigate the bacterial factors underlying divergence in the host response to high and low transmission isolates.


Uganda 2021-08-24 2024-08-24 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Peter Elyanu James
ID: UNCST-2021-R013210
 CoVPN 3008- UBUNTU Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. Version 1.0, dated 16 May 2021. DAIDS Document ID # 38838.
REFNo: HS1642ES

Primary Objectives
The primary objectives of this study are to determine the following:
1. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in adults who are at risk of severe COVID-19
2. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
3. To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19

Secondary Objectives
The secondary objectives of this study are to evaluate the following:
1. Durability of VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 through the final study visit (Month 12 post-dose 1) in volunteers with no previous COVID-19
2. VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19
3. VE of COVID-19 mRNA vaccine against SARS-CoV-2 infection defined by nucleocapsid protein seroconversion regardless of symptomology in volunteers with no previous COVID-19
4. VE of COVID-19 mRNA vaccine against asymptomatic SARS-CoV-2 infection defined by nucleocapsid protein seroconversion without prior occurrence of the symptomatic COVID-19 primary endpoint in volunteers with no previous COVID-19
5. Post -vaccination immune response markers as correlates of risk of COVID-19 and as correlates protection against COVID-19
6. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in all participants regardless of baseline SARS-CoV-2 status

Exploratory Objectives
The exploratory objectives of this study are to evaluate the following:
1. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 by baseline HIV infection status in volunteers with no previous COVID-19 and in all volunteers regardless of previous COVID-19 status
2. VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19 and in all volunteers regardless previous COVID-19 status
3. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in volunteers with previous COVID-19
4. Relative rate of COVID-19 and severe COVID-19 in placebo recipients with previous COVID-19 compared to vaccine recipients with no previous COVID-19
5. Assess T-cell responses in placebo recipients who develop COVID-19 compared to vaccine recipients who develop symptomatic COVID-19
6. Assess incidence of adverse birth outcomes among pregnant persons enrolled in the trial

 Uganda 2021-08-24 2024-08-24 Medical and Health Sciences Clinical Trial Non-degree Award
Perez Mujuni Perez Mbiire Batwine
ID:
Teachers' welfare, human capital and performance of Government aided primary school in Isingiro District
REFNo: SS964ES

i. To establish the relationship between teachers’ welfare and performance of government aided primary schools in Isingiro District.
ii. To establish the relationship between human capital and performance of government aided primary schools in Isingiro District.
iii. To find out the effect of combining teachers’ welfare and human capital on the performance of government aided primary schools in Isingiro District.
iv. To find out whether monitoring systems mediates teachers’ welfare and the performance of government aided primary schools in Isingiro District.
v. To find out whether monitoring systems mediates human capital and the performance of government aided primary schools in Isingiro District.

 Uganda 2021-08-23 2024-08-23 Social Science and Humanities Non-Clinical Trial Degree Award
Hasifah Namatovu Kasujja
ID:
eHealth Adoption in Uganda. What is the status? eHAU
REFNo: SS945ES

1. To inventory existing eHealth interventions in Uganda to ascertain maturity, failure and successes
2. To study the barriers and facilitators of eHealth adoption in Uganda
3. To develop a framework for successful eHealth adoption
4. To evaluate the framework for utility

 Uganda 2021-08-23 2024-08-23 Social Science and Humanities Non-Clinical Trial Non-degree Award
Ronald Kiguba
ID: UNCST-2019-R000844
 Two-way risk communication mobile application use versus traditional methods of adverse drug reaction reporting in Uganda: a cluster-randomized controlled trial
REFNo: HS1366ES

This study will: i) assess the feasibility of implementing a mobile app for the reporting of ADRs associated with DTG and IPT at selected ART-sites in Uganda; ii) describe the characteristics (causality, seriousness, completeness, unexpectedness, severity, outcome) of the DTG- and IPT-linked ADR-reports submitted to NPC using the mobile app; and, iii) determine if use of the mobile app versus existing methods of ADR-reporting (paper-form and web-form) increases by 25% the number of reported ADRs linked to DTG and IPT use during 2.5 years of follow-up, iv) determine the cost and cost-effectiveness of using the mobile app versus existing methods of ADR-reporting.
 Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Clinical Trial Non-degree Award
Cissy  Kityo
ID: UNCST-2021-R013663
 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern.
REFNo: HS1669ES

-To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent
virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in
adults who are at risk of severe COVID-19 -2. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19 -3. To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19
Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Clinical Trial Non-degree Award
Philippa Musoke
ID: UNCST-2021-R013523
 ViiV 205858: Open-label access to dolutegravir for HIV-1 infected children and adolescents completing IMPAACT Studies P1093 and P2019 Version 4.0 dated 10 Dec 2020
REFNo: HS1453ES

Primary
• To provide access to age appropriate formulations of dolutegravir (DTG), either as single entity DTG or as fixed dose combination (FDC) abacavir/dolutegravir/lamivudine (ABC/DTG/3TC), in an open-label protocol to eligible participant s who have completed the P1093 or P2019 parent studies.

Secondary

To assess any serious adverse events (SAEs) and any clinical or laboratory adverse events that lead to the discontinuation of IP (DTG or ABC/DTG/3TC FDC).
 Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Clinical Trial Non-degree Award
Baker Lukwago
ID: UNCST-2021-R013259
 Tracking DISC project activities through integrated surveys in Uganda_Version One May 2021
REFNo: HS1481ES

This research protocol includes the DISC research that will happen from 2021 to 2024 in the DISC project’s focus geographies. The methods include several annual rounds of data collection, with 4 research methodologies: provider surveys, client exit interviews (CEIs), Household Surveys (HHS), and two follow up surveys with the individuals who participate in the CEIs.

Research Objectives
1. To understand exposure to information about self-injectable contraceptives in the DISC sentinel areas.
2. To understand knowledge and attitudes about self-injectable contraceptives among women in DISC sentinel areas.
3. To understand sexual and reproductive health empowerment among women of reproductive age and SI users in DISC sentinel areas.
4. To understand users’ experiences with self-injection training
5. To understand providers’ knowledge and attitudes regarding self-injectable contraceptive service provision.
6. To understand initiation and continuation of self-injection following training.
7. To gain lessons regarding client exit survey methodology for future survey implementation among self-inject clients.
8. To gain learnings regarding follow-up methodologies for future survey implementation among self-inject clients, particularly as relates to continuation measurement.

 Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Deo Wabwire Ogema
ID: UNCST-2021-R013932
 COVPN 3008: Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. Version 1.0 16 May 2021
REFNo: HS1659ES

The primary objectives are:
•To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in adults who are at risk of severe COVID-19
•To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
•To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19

Secondary objectives are to evaluate the following:
•Durability of VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 through the final study visit (Month 12 post-dose 1) in volunteers with no previous COVID-19
•VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19
•VE of COVID-19 mRNA vaccine against SARS-CoV-2 infection defined by nucleocapsid protein seroconversion regardless of symptomology in volunteers with no previous COVID-19
•VE of COVID-19 mRNA vaccine against asymptomatic SARS-CoV-2 infection defined by nucleocapsid protein seroconversion without prior occurrence of the symptomatic COVID-19 primary endpoint in volunteers with no previous COVID-19
•Post -vaccination immune response markers as correlates of risk of COVID-19 and as correlates protection against COVID-19
•VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in all participants regardless of baseline SARS-CoV-2 status
gestational age)
The exploratory objectives are to evaluate:
•VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 by baseline HIV infection status in volunteers with no previous COVID-19 and in all volunteers regardless of previous COVID-19 status
•VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19 and in all volunteers regardless previous COVID-19 status
•VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in volunteers with previous COVID-19
•Relative rate of COVID-19 and severe COVID-19 in placebo recipients with previous COVID-19 compared to vaccine recipients with no previous COVID-19
•Assess T-cell responses in placebo recipients who develop COVID-19 compared to vaccine recipients who develop symptomatic COVID-19
•Assess incidence of adverse birth outcomes among pregnant persons enrolled in the trial

 Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Clinical Trial Non-degree Award
Edwin Nuwagira
ID: UNCST-2021-R013488
 Improving Pulmonary function after Tuberculosis (IMPACT) at Mbarara Regional Referral Hospital. The incidence, clinical characteristics and factors associated with post-tuberculosis obstructive pulmonary disease at Mbarara Regional Referral Hospital (MRRH)
REFNo: HS1579ES

To determine the incidence, clinical characteristics and factors associated with post-tuberculosis obstructive pulmonary disease at Mbarara Regional Referral Hospital ,
 Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Non-Clinical Trial Degree Award
Umaru Ssekabira Byansansa
ID:
Assessing COVID-19 sero-prevalence from routine antenatal care visits in Moyo and Adjumani Districts, Uganda, 2021-2022
REFNo: HS1628ES

The aim of this activity is to determine COVID-19 sero-prevalence from women attending antenatal clinics for their first ANC visit in Moyo and Adjumani Districts from April 2021 to September 2022.
The specific objectives of this sero-prevalence assessment shall be to:
•Measure the sero-prevalence of antibodies to COVID-19 in the population of pregnant women attending first ANC by age group, in order to ascertain the cumulative population immunity
•Monitor trends and detect emerging hotspots of COVID-19 in selected geographic areas

 Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Doreen Chemutai
ID:
Pathways, Perceptions and Performance: A comparative Analysis of Women on Open and Reserved Seats in Uganda’s 10th Parliament
REFNo: SS971ES

i. To comparatively analyze the motives of women MPs on the reserved and open seats for seeking parliamentary seats in Uganda’s 10th parliament.
ii. To document the experiences of women members of parliament on the reserved and open seats of their journey to parliamentary seats.
iii. To explain voter’s perceptions of performance of women members of parliament on reserved and open seats.
iv. To evaluate the performance differences of women MPs on the reserved and opens seats of representation and legislation

 Uganda 2021-08-20 2024-08-20 Social Science and Humanities Non-Clinical Trial Degree Award
Annet Nanvubya
ID: UNCST-2025-R015525
 Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern version 1.0 16-05-2021.
REFNo: HS1677ES

Primary Objectives
The primary objectives of this study are to determine the following:
• To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in adults who are at risk of severe COVID-19
• To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
• To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19

Secondary Objectives

The secondary objectives of this study are to evaluate the following:
• Durability of VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 through the final study visit (Month 12 post-dose 1) in volunteers with no previous COVID-19
• VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19
• VE of COVID-19 mRNA vaccine against SARS-CoV-2 infection defined by nucleocapsid protein seroconversion regardless of symptomology in volunteers with no previous COVID-19
• VE of COVID-19 mRNA vaccine against asymptomatic SARS-CoV-2 infection defined by nucleocapsid protein seroconversion without prior occurrence of the symptomatic COVID-19 primary endpoint in volunteers with no previous COVID-19
• Post -vaccination immune response markers as correlates of risk of COVID-19 and as correlates protection against COVID-19
• VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in all participants regardless of baseline SARS-CoV-2 status
gestational age)

Exploratory Objectives
The exploratory objectives of this study are to:
• VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 by baseline HIV infection status in volunteers with no previous COVID-19 and in all volunteers regardless of previous COVID-19 status
• VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19 and in all volunteers regardless previous COVID-19 status
• VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in volunteers with previous COVID-19
• Relative rate of COVID-19 and severe COVID-19 in placebo recipients with previous COVID-19 compared to vaccine recipients with no previous COVID-19
• Assess T-cell responses in placebo recipients who develop COVID-19 compared to vaccine recipients who develop symptomatic COVID-19
• Assess incidence of adverse birth outcomes among pregnant persons enrolled in the trial


 Uganda 2021-08-20 2024-08-20 Medical and Health Sciences Clinical Trial Non-degree Award
Judith Kobusinge
ID:
Effect of selected soil moisture conservation practices on water budgeting in Robusta coffee in Uganda
REFNo: A117ES

1) To predict the effect of soil moisture on Robusta coffee production and productivity in Uganda. 2) To estimate the water use efficiency (WUE) of Robusta coffee at various phenological stages under Albizia coriaria and Open sun 3) To determine the effect of selected soil moisture conservation practices on soil-water relations in Robusta coffee agro-systems.
Uganda 2021-08-19 2024-08-19 Agricultural Sciences Non-Clinical Trial Degree Award
Patrick OJOK
ID:
Teachers’ Perceived Preparedness to Implement the Competency-Based Lower Secondary Curriculum
REFNo: SS810ES

Purpose of the Study The primary purpose of this study is to determine the perceptions of preparedness of lower secondary teachers and explore the factors hindering and/or facilitating the implementation of the new LS curriculum in Uganda. Research Objectives 1) Determine the perceived preparedness of lower secondary school teachers to implement the new lower secondary curriculum. 2) Explore the school and teacher-factors that facilitate/hinder the implementation of the new lower secondary curriculum. 3) Identify the support that lower secondary teachers need to improve their capacity to implement the new LS curriculum.
Uganda 2021-08-19 2024-08-19 Social Science and Humanities Non-Clinical Trial Non-degree Award
Christopher Dolan Gerald
ID:
"changing gender norms and gender-responsive humanitarian action in Uganda”
REFNo: SS858ES

 To examine gendered norms, roles and power relations changed during and after forced displacement;
 To explore how existing knowledge on gender issues informed design of the current refugee response; and
 To find out implications for humanitarian agencies of observed changes in gender roles, norms and power relations

 UK 2021-08-17 2024-08-17 Social Science and Humanities Non-Clinical Trial Non-degree Award
Elizabeth Najjingo
ID:
Factors that influence false tooth extraction among children below two years in Isingiro, Southwestern Uganda.
REFNo: SS952ES

To explore alternatives that can be used instead of false tooth extraction,To explore outcomes of the practice false tooth extraction,To identify methods used for false tooth extraction in Isingiro district.,To explore factors responsible for false tooth extraction within Isingiro district.,To explore factors responsible for the practice of false tooth extraction and methods used in Isingiro district in South Western Uganda.,
 Uganda 2021-08-17 2024-08-17 Social Science and Humanities Non-Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS